COVID Advisory Group LETHALLY INCOMPETENT - No Second Wave
72 views
•
Published 3 years ago
•
The UK government’s Scientific Advisory Group for Emergencies (SAGE) has got many things about the Covid-19 pandemic wrong, says Dr Mike Yeadon
Dr. Michael Yeadon is an Allergy & Respiratory Therapeutic Area expert with 23 years in the pharmaceutical industry. He trained as a biochemist and pharmacologist, obtaining his PhD from the University of Surrey (UK) in 1988.
Dr. Yeadon then worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, PAF, NO and lung inflammation. With colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers.
Joining Pfizer in 1995, he was responsible for the growth and portfolio delivery of the Allergy & Respiratory pipeline within the company. He was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008.
Under his leadership the research unit invented oral and inhaled NCEs which delivered multiple positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive collaborations such as with Rigel Pharmaceuticals (SYK inhibitors) and was involved in the licensing of Spiriva and acquisition of the Meridica (inhaler device) company.
Dr. Yeadon has published over 40 original research articles and now consults and partners with a number of biotechnology companies. Before working with Apellis, Dr. Yeadon was VP and Chief Scientific Officer (Allergy & Respiratory Research) with Pfizer.
Dr Yeadon is a co-founder of Ziarco and CEO. He is an Allergy & Respiratory therapeutic area expert, developed out of deep knowledge of biology & therapeutics, and is an innovative drug discoverer with over 25 years of experience in drug discovery and development. Dr Yeadon has published over 40 original research articles and since 2011 hasconsulted to more than 20 biotechnology companies. Prior to consulting as an independent, he was Vice President and Chief Scientific Officer of the A&R Research Unit of Pfizer. At Pfizer, Dr Yeadon was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008. Under his leadership the unit invented oral and inhaled NCEs which delivered positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive external collaborations and was involved in product and device licensing.
Prior to Pfizer, Dr Yeadon worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, NO and lung inflammation. With colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers. He attended the University of Surrey in Guildford, U.K, where he received his PhD (under Professor Ian Kitchen), with thesis work in the respiratory field, and a BSc, First Class, with Joint Honours, in Biochemistry and Toxicology.
Dr. Michael Yeadon is an Allergy & Respiratory Therapeutic Area expert with 23 years in the pharmaceutical industry. He trained as a biochemist and pharmacologist, obtaining his PhD from the University of Surrey (UK) in 1988.
Dr. Yeadon then worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, PAF, NO and lung inflammation. With colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers.
Joining Pfizer in 1995, he was responsible for the growth and portfolio delivery of the Allergy & Respiratory pipeline within the company. He was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008.
Under his leadership the research unit invented oral and inhaled NCEs which delivered multiple positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive collaborations such as with Rigel Pharmaceuticals (SYK inhibitors) and was involved in the licensing of Spiriva and acquisition of the Meridica (inhaler device) company.
Dr. Yeadon has published over 40 original research articles and now consults and partners with a number of biotechnology companies. Before working with Apellis, Dr. Yeadon was VP and Chief Scientific Officer (Allergy & Respiratory Research) with Pfizer.
Dr Yeadon is a co-founder of Ziarco and CEO. He is an Allergy & Respiratory therapeutic area expert, developed out of deep knowledge of biology & therapeutics, and is an innovative drug discoverer with over 25 years of experience in drug discovery and development. Dr Yeadon has published over 40 original research articles and since 2011 hasconsulted to more than 20 biotechnology companies. Prior to consulting as an independent, he was Vice President and Chief Scientific Officer of the A&R Research Unit of Pfizer. At Pfizer, Dr Yeadon was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008. Under his leadership the unit invented oral and inhaled NCEs which delivered positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive external collaborations and was involved in product and device licensing.
Prior to Pfizer, Dr Yeadon worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, NO and lung inflammation. With colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers. He attended the University of Surrey in Guildford, U.K, where he received his PhD (under Professor Ian Kitchen), with thesis work in the respiratory field, and a BSc, First Class, with Joint Honours, in Biochemistry and Toxicology.
Keywords
immunitydrmichaelsystemimmunemikeflueimmunologistcovidsecond wavet cellt-cellyeadon
FREE email alerts of the most important BANNED videos in the world
Get FREE email alerts of the most important BANNED videos in the world that are usually blacklisted by YouTube, Facebook, Google, Twitter and Vimeo. Watch documentaries the techno-fascists don't want you to know even exist. Join the free Brighteon email newsletter. Unsubscribe at any time. 100% privacy protected.
Your privacy is protected. Subscription confirmation required.
Related videos